Compare Citius Pharmaceuticals Inc (CTXR) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares Core S&P 500 ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while iShares Core S&P 500 ETF trades at $756.22. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | IVV | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $763.10 |
52-Week Low | $0.53 | $624.65 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
IVV trades at $752.57, down 0.77% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF approaches key resistance near $756-$760 with support at $750-$745. Recent news highlights ongoing AI-driven market dynamics and analyst optimism for S&P 500 targets reaching 8,000+ by year-end, though concerns about valuation and earnings season catalysts persist.
The outlook remains positive with strong institutional sentiment and technical momentum, but stretched valuations and potential market volatility present near-term risks. Earnings season performance will be critical for sustaining the current rally toward record highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
